Nasdaq

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

The Phase 1 clinical trial currently recruiting is a pharmacokinetic bridging study in the U.S. designed as a single-dose, single-center, open-label, randomized 2-way crossover study of TH104 and an ...

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceu…

Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and ...

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
Seeking Alpha

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

SALT LAKE CITY, March 26, 2025 /PRNewswire/ -- Lipocine Inc. (LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today ...
Seeking Alpha

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
Business Wire

Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding RNA-based compound designed to provide a ...
Business Wire

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...
Morningstar

Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)

ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400 patients; topline results are expected by Q4 2026 Evenamide is a ...
Nasdaq

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ...
Morningstar

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory ...

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US ...